138 related articles for article (PubMed ID: 38418136)
21. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
[TBL] [Abstract][Full Text] [Related]
22. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
23. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
24. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
25. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
27. CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
Matsunaga T; Saito H; Kuroda H; Osaki T; Takahashi S; Iwamoto A; Fukumoto Y; Taniguchi K; Fukuda K; Miyauchi W; Shishido Y; Miyatani K; Fujiwara Y
BMC Cancer; 2022 Apr; 22(1):418. PubMed ID: 35428212
[TBL] [Abstract][Full Text] [Related]
28. Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Baetz T
J Immunother; 2021 Jan; 44(1):41-48. PubMed ID: 32815895
[TBL] [Abstract][Full Text] [Related]
29. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study.
Akazawa Y; Yoshikawa A; Kanazu M; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2022 Sep; 13(17):2450-2458. PubMed ID: 35820673
[TBL] [Abstract][Full Text] [Related]
30. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
31. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
[TBL] [Abstract][Full Text] [Related]
34. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
[TBL] [Abstract][Full Text] [Related]
35. Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness.
Cortijo-Cascajares S; Cercós-Lletí AC; Ortiz-Pérez S; Caro-Teller JM; Ferrari-Piquero JM
J Oncol Pharm Pract; 2023 Mar; 29(2):290-298. PubMed ID: 34907812
[TBL] [Abstract][Full Text] [Related]
36. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
37. Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.
Nakamura H; Shionoya A; Arihara Y; Hayasaka N; Kubo T; Usami M; Sugita S; Uhara H; Takada K
Front Immunol; 2023; 14():1259071. PubMed ID: 37753079
[TBL] [Abstract][Full Text] [Related]
38. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.
Teraoka S; Fujimoto D; Morimoto T; Kawachi H; Ito M; Sato Y; Nagata K; Nakagawa A; Otsuka K; Uehara K; Imai Y; Ishida K; Fukuoka J; Tomii K
J Thorac Oncol; 2017 Dec; 12(12):1798-1805. PubMed ID: 28939128
[TBL] [Abstract][Full Text] [Related]
39. Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab.
Hara Y; Baba Y; Toihata T; Harada K; Ogawa K; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Baba H
J Gastrointest Oncol; 2022 Dec; 13(6):2779-2788. PubMed ID: 36636073
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
